Looks extremely bullish - definitely watching this stock. If price drops to $9, definitely a buy. Australia based firm has some key cancer drugs in the pipeline.
(1) Price above Kumo
(2) Future Kumo bullish
(3) Senkou span A & B with positive slope
(4) Both Tenkan Sen & Kijun Sen have +ve slopes
(5) Chikou Span above the price & free to go up
(6) ADX > 25
US FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG
With RPDD granted, Kazia may now be eligible to receive a 'rare pediatric disease priority review voucher' (PRV) if paxalisib is approved for DIPG
A PRV grants the holder an expedited six-month review of a new drug application by FDA.
PRVs can be sold to other companies...
What is KZIA?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being...
Kazia Therapeutics Ltd. engages in the pharmaceutical drug research and development. Its pipeline includes two clinical-stage drug development candidates such as GDC-0084, and Cantrixil. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.